Pasithea Therapeutics Corp. (KTTA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.41
- As of
Kresmion compiles this page from KTTA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Pasithea Therapeutics Corp. (KTTA): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-16.
See the full KTTA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for KTTA on one page. Preview it with sample data, then open it live with a free account.
Preview the KTTA dossierActive signals for KTTA
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +205% to KTTA (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +204% to KTTA (2026Q1)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 57% of KTTA (2026Q1)
- mediumEARNINGS_MISS
Q1-2022: Missed consensus by 243.1% - EPS $-1.4 vs $-0.408 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 73.9% - EPS $-0.12 vs $-0.459 estimate
FREE, NO ACCOUNT
Every signal on KTTA, as it fires
You are seeing 5 of 8 signals recorded on KTTA since 2026-05-31.
The five above landed across 3 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KTTA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 70261F202 · 2026Q2 | $34K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 70261F202 · 2026Q2 | $33K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KTTA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
KTTA against its peers
KTTA's return on equity of -37.0% ranks in the 92nd percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | KTTA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 675097 | n/a | 12 |
| Operating margin | n/a | -1151.1% | n/a | 10 |
| Net margin | n/a | -1142.6% | n/a | 10 |
| Return on equity | -37.0% | -115.6% | 92 | 18 |
| 1 year | -43.3% | -56.0% | 66 | 15 |
Peers (21): TVRD, ICU, CYCN, CLRB, ALLR, DARE, LTRN, BCDA, INAB, NCEL, PTN, CKDXF, LSTA, HIND, LPCN, INTI, SYBX, AEON, TPST, PASG, MRKR. Left out: CTXR (no annual filing), HOOK (period gap), FNCHQ (period gap), ZIVO (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (KTTA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow KTTA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to KTTA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.